甲磺酸阿帕替尼治疗晚期原发性肝癌的临床疗效及安全性  

Clinical effect and safety of apatinib mesylate in the treatment of advanced primary liver cancer

作　　者：郑艳[1] 林鑫[1] ZHENG Yah;LIN Xin.(Department of Oncology, Fujian Provincial Hospital, Fuzhou 350000, Chin)

机构地区：[1]福建省立医院肿瘤内科,福建省福州市350000

出　　处：《临床合理用药杂志》2018年第6期32-33,35,共3页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨甲磺酸阿帕替尼治疗晚期原发性肝癌的临床疗效及其安全性。方法选取福建省立医院2014年12月—2016年12月收治的晚期原发性肝癌患者60例,随机分为研究组和对照组,各30例。研究组患者给予甲磺酸阿帕替尼治疗,对照组患者给予淀粉安慰剂。比较两组患者临床缓解率、生存期及毒副反应发生情况。结果研究组患者临床缓解率高于对照组(P<0.05)。随访1年,研究组患者生存期长于对照组(P<0.05)。两组患者各毒副反应发生率比较,差异无统计学意义(P>0.05)。结论采用甲磺酸阿帕替尼治疗晚期原发性肝癌的临床疗效确切,可有效延长患者生存期,且安全性较好。Objective To investigate the clinical effect and safety of apatinib mesylate in the treatment of advanced primary liver cancer. Methods A total of 60 cases of advanced primary liver cancer patients were selected from December 2014 to December 2016 in Fujian Provincial Hospital,which were randomly divided into study group and control group,30 cases in each group. Study group was treated with apatinib mesylate,control group was treated with placebo. The clinical remission rate,survived time and toxic and side effects were compared between the two groups. Results The study group of clinical remission rate was higher than control group（ P〈0. 05）. Followed-up for 1 year,the survived time of study group was longer than control group（ P〈0. 05）. No significant difference of the incidence rate of toxic and side effects was found between the two groups（ P〉0. 05）. Conclusion Mesylate apatinib has an exactly clinical effect in treating advanced primary liver cancer,it can effectively prolong the survival time of patients,and with higher safety.

关 键 词：肝肿瘤 甲磺酸阿帕替尼 安全性 治疗结果 

分 类 号：R735.7[医药卫生—肿瘤]